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ABSTRACT
Angiogenesis represents a hallmark of tumor progression in Multiple Myeloma 
(MM), a still incurable malignancy. Here we analyzed the activity of cytokine-
stimulated NK cells against tumor-associated endothelial cells isolated from bone 
marrow aspirates of MM patients with active disease (MMECs). We show that NK cells 
activated with optimal doses of IL-15 killed MMECs thanks to the concerted action 
of multiple activating receptors. In particular, according to the high expression of 
PVR and Nectin-2 on MMECs, DNAM-1 actively participated in target recognition. 
Interestingly, in MMECs the surface density of PVR was significantly higher than 
that detected in endothelium from patients with MM in complete remission or with 
monoclonal gammopathy of undetermined significance (MGUS). Importantly, IL-
27, which unlike IL-15 does not display pro-angiogenic properties, maintained or 
increased the NK cell functions induced by suboptimal concentrations of IL-15. NK cell 
properties included killing of MMECs, IFN-γ production as well as a peculiar increase 
of NKp46 expression on NK cell surface. Finally, IL-27 showed a striking capability 
of up-regulating the expression of PD-L2 and HLA-I on tumor endothelium, whereas 
it did not modify that of PD-L1 and HLA-II. 
Our results suggest that cytokine-activated endogenous or adoptively transferred 
NK cells might support conventional therapies improving the outcome of MM patients.
INTRODUCTION
In the last decades important advancements in 
the treatment of different malignances have led to 
significant improvement in patients’ survival. A variety 
of therapies are currently available including those 
targeting specific pathways involved in the growth and 
survival of cancer cells or tumor-associated stromal cells 
such as endothelial cells. A pro-tumoral crosstalk between 
cancer and endothelial cells occurs and is essential for 
tumor growth. In multiple myeloma (MM), an incurable 
malignancy of monoclonal plasma cells [1], angiogenesis 
represents a hallmark of tumor progression and anti-
VEGF drugs, alone or in combination with other agents, 
are currently used. In some patients however, available 
therapeutic approaches resulted in limited benefits and in 
a short-lasting tumor regression. Thus, many efforts have 
been made to evaluate additional therapeutic protocols 
aimed at obtaining a more durable tumor control in 
different malignances including MM. New strategies 
consist of immunotherapeutic approaches including the 
strengthening of the function of endogenous Natural 
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Killer (NK) cells or the adoptive transfer of “armed” 
or activated NK cells [2–5]. These cells are cytotoxic 
members of the Innate Lymphoid Cell (ILCs) family [6, 7] 
and have been shown to play a crucial role in tumor 
surveillance also due to their capability of killing tumor 
cells including those with stem cell like properties [8–11]. 
The mechanisms allowing the NK-mediated recognition 
of tumor cells have been largely clarified and consist 
of the cooperation of different triggering receptors that 
are engaged by specific ligands upregulated or de novo 
expressed on transformed cells [3, 11, 12]. Activating 
NK receptors are represented by NKp46 (CD335), 
NKp30 (CD337) and NKp44 (CD336) (collectively 
termed natural cytotoxicity receptors, NCR), DNAM-1 
(CD226) and NKG2D (CD314) [3, 13]. Although viral 
glycoproteins have been identified as ligands for NCR, 
their cellular ligands are not fully defined [14].  Two 
molecules, the mixed-lineage leukemia (MLL5) [15] 
and B7-H6 [16] have been found to be expressed on a 
wide panel of tumors [17] and represent cellular surface 
ligands of NKp44 and NKp30, respectively. It is of note 
however, that different evidences suggest that NKp30 
would be able to recognize additional, still undefined, 
tumor-associated ligand(s). NKG2D recognizes MICA/B 
and ULBPs [12] stress inducible molecules de-novo 
expressed after tumor transformation and virus infection. 
DNAM-1 binds PVR (CD155) and Nectin-2 [18], two 
members of the Nectin family that are also recognized 
by Tactile [19] and TIGIT [20]. PVR and Nectin-2 are 
over-expressed in tumors of different histotype and 
their interaction with DNAM-1 is non-redundant and 
crucial to obtain an efficient tumor cell killing [21–24]. 
Accordingly, different studies highlighted the importance 
of DNAM-1/ligands interactions in the establishment of 
the activating immunological synapse that allows tumor 
recognition by both NK and T cells [25–28]. 
The possible effect of NK-cell based therapeutic 
approaches in killing of tumor-associated endothelial cells 
with the consequent reduction of the vascular network 
remains to be determined. 
In the present study we analyzed the NK cell 
activity against tumor-associated endothelial cells (EC) 
isolated from bone marrow aspirates of MM patients in 
active phase (MMECs). We evaluated the susceptibility of 
MMECs to killing mediated by IL-15-stimulated NK cells 
and dissected the molecular interactions occurring between 
effector and target cells. Moreover, we investigated the 
immunostimulatory effects of IL-27 [29] that, unlike 
IL-15, does not display pro-angiogenic properties [30, 31]. 
Finally, considering that NK cell activation might result 
in vivo in a cytokine storm responsible for the activation 
of immune checkpoints, [32, 33] we analyzed in MMECs 
the constitutive and cytokine-induced surface expression 
of Programmed Death Ligands (PD-Ls) and HLA 
class I and II [34–36]. 
RESULTS
DNAM-1 actively participates to the killing of 
MMECs mediated by rIL-15-activated NK cells 
Tumor-associated endothelial cells were isolated from 
bone marrow (BM) aspirates of nine Multiple Myeloma 
Patients in active phase (Table 1) [37]. MMECs were 
analyzed for the susceptibility to lysis mediated by peripheral 
blood mononuclear cells (PBMCs) of healthy donors 
activated with optimal doses of rIL-15 (20 ng/ml) (Figure 
1A). Overall, activated PBMCs killed the MMECs analyzed 
and HLA class I molecules had a poor protective role as 
demonstrated by the lack of significant differences observed 
in the presence of the anti-HLA-I mAb (Figure 1A). It is 
of note however that a certain degree of heterogeneity in 
the susceptibility of MMECs to activated PMBCs could 
be appreciated. Indeed, MMEC3 and MMEC4 showed a 
susceptibility to lysis comparable to that of EA, a prototypic 
tumor endothelial cell line used as control, whereas MMEC1 
and MMEC2 were more resistant (Figure  1A). 
Assuming a predominant role of NK lymphocytes in the 
killing of MMECs by rIL-15 activated PBMCs, we analyzed 
the susceptibility of MMECs to lysis mediated by highly 
purified activated NK cells (Figure 1B). Moreover, in order to 
analyze the possible contribution of the different activating NK 
receptors in the recognition of MMECs, cytolytic assays were 
performed in the presence of mAbs able to specifically disrupt 
the interactions between the receptors (on NK cells) and their 
ligands (on target cells). Similar to EA, MMECs were highly 
susceptible to killing mediated by rIL-15 activated NK cells, a 
process that depended on the cooperation of various activating 
receptors (Figure 1B). In particular, NKG2D and DNAM-1 
contributed to the killing of MMEC3 and a significant 
inhibition of lysis was observed only after the combined 
mAb-mediated masking of both molecules. NKG2D was 
not involved in MMEC5 recognition, whereas DNAM-1 
played a major role in the NK-mediated cytotoxicity, as its 
mAb-mediated masking resulted in a significant reduction 
of lysis. Moreover, mAb-mediated masking of NKp30 
and NKp46 significantly reduced the lysis demonstrating 
the involvement of these receptors in killing of MMEC5 
(Figure 1B). The NK-mediated recognition of EA cells 
involved the four different activating receptors thus 
recapitulating what observed in endothelial cells derived 
from MM patients. A similar scenario was observed 
using endothelial cells obtained from patients with 
monoclonal gammopathy of undetermined significance 
(MGECs). In these experiments we used the CD107a 
assay that was more suitable to preserve the viability of 
target cells. As shown in Supplementary Figure 1, rIL-15 
stimulated NK cells degranulated in the presence of MGECs 
(and in the presence of EA, used as control) and DNAM-1, 
NKG2D, NKp30 and NKp46 receptors clearly cooperated in 
the process. 
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MMECs and EA cell line express the ligands of 
DNAM-1 activating receptor
MMECs were analyzed for the surface expression 
of the ligands of activating receptors known to regulate 
NK cell functions including cytolytic activity. The 
gating strategy is shown in Supplementary Figure  2. For 
comparison, the analysis was performed on endothelial 
cells derived from BM of patients with MM in complete 
remission (cr-MMEC), monoclonal gammopathy of 
undetermined significance (MGEC 1-5) or anemia due to 
iron deficiency (IDAEC). 
In all cells analyzed NKG2D-ligands were either 
undetectable or expressed at very low levels (Table 2). 
In particular, according to the involvement of NKG2D 
in NK-mediated lysis (see Figure 1B) MMEC3 
expressed MICA, ULBP-2 and ULBP-3.  The latter two 
ligands were also detected in the EA cell line whereas 
MMEC5, which was killed in an NKG2D-independent 
manner, did not express any of the NKG2D ligands 
analyzed. All endothelial cells analyzed expressed 
good levels of PVR and Nectin-2 (Table 2), ligands of 
DNAM-1 receptor involved in the killing of MMECs 
and EA (see Figure 1B). Interestingly, in MMECs and 
EA the surface density of PVR was significantly higher 
than in cr-MMEC, MGECs and IDAEC (Figure 2A). 
Accordingly, MMECs and EA but not the other 
endothelial cells analyzed were stained by the DNAM-
1-Fc soluble receptor (Figure 2B). 
In spite of the clear involvement of NKp30 in the 
NK-mediated lysis of some MMECs and EA cells, none of 
the endothelial cells analyzed was stained by the NKp30-
Fc soluble receptor (Figure 2B), which efficiently bound 
the B7-H6 specific ligand on B7-H6+ cell transfectants and 
K562 cell line   (Supplementary Figure 3A). EA cell line 
was characterized by a very low level of B7-H6 transcript, 
comparable to that detected in immature Dendritic cells 
(iDC), whose interaction with NK cells is mostly NKp30-
dependent [38, 39] (Supplementary Figure 3B). Lack of 
staining of NKp30-Fc soluble receptor on MMECs might 
be due to the poor surface expression of B7-H6, not 
sufficient to bind NKp30-Fc soluble receptor, but capable 
of engaging the native NKp30 receptor. Alternatively, 
both MMECs and iDC may express an additional, not 
yet identified, NKp30 ligand that is not recognized by the 
NKp30-Fc soluble receptor. 
rIL-27 plus suboptimal doses of rIL-15 enhance 
NK cell cytotoxicity against tumor endothelial 
cells
NK cells stimulated with optimal doses of rIL-15 
displayed cytotoxicity against all MM-associated 
endothelial cells analyzed, an effect that was accompanied 
by the upregulated expression of CD69 activation marker 
(Figure 3B and 3C), NKG2D (Figure 3D) and NKp30 
(Figure 3E) and by a modest but significant production 
of IFN-γ (Figure 3H). However, IL-15 might exert 
Table 1: Endothelial cells analyzed in the study
Endothelial cells Disease Phase Age Gender
MMEC1 MM Active 55 Male
MMEC2 MM Active 63 Female
MMEC3 MM Active 70 Male
MMEC4 MM Active 67 Female
MMEC5 MM Active 73 Female
MMEC6 MM Active 55 Male
MMEC7 MM Active 65 Male 
MMEC8 MM Active 60 Female
MMEC9 MM Active 63 Female
cr-MMEC MM Complete remission 71 Male
MGEC1 MGUS 47 Male
MGEC2 MGUS 59 Male
MGEC3 MGUS 61 Female
MGEC4 MGUS 75 Female
MGEC5 MGUS 53 Male
MGEC6 MGUS 75 Male
MGEC7 MGUS 64 Male
IDAEC IDA 56 Female
The endothelial cells analyzed in this study were derived from bone marrow aspirates of patients with Multiple Myeloma 
in active phase (MMEC1-9) or complete remission (cr-MMEC), patients with monoclonal gammopathy of undetermined 
significance (MGEC1-7) and a patient with anemia due to iron deficiency (IDAEC).
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unwanted in vivo side effects due to its strong pro-
angiogenic activity. Thus, we analyzed the function of 
NK cells cultured in the presence of rIL-27 (100 ng/ml), 
which has been described to combine immunostimulatory 
and anti-angiogenic properties. As shown in Figure 3, 
the stimulatory capability of rIL-27 was lower than that 
of rIL-15. In particular, rIL-27 induced a slight increase 
in NK cell-mediated killing of EA cells (Figure 3A), a 
modest increase in the surface expression of CD69 and 
NKG2D, and did not stimulate the release of IFN-γ. It is of 
note, however, that rIL-27 caused a peculiar upregulation 
of the NKp46 receptor (Figure 3F). When used in 
combination with rIL-15, rIL-27 did not improve CD69 
and NKG2D upregulation but significantly increased the 
cytolytic activity, the surface expression of NKp30 and the 
IFN-γ production as compared to rIL-15 alone (Figure 3). 
DNAM-1 expression was not modified by rIL-27 or rIL-15 
used either alone or in combination (Figure 3G).
To determine the dose of cytokines suitable to induce 
NK cell activation minimizing pro-angiogenic side effects, 
NK cells were treated with rIL-27 in combination with 
decreasing concentration of rIL-15, ranging from 20 to 
1 ng/ml (Figure 4). NK cells stimulated with rIL-27 and 
the lowest rIL-15 concentration used (1 ng/ml) showed a 
significant increased expression of CD69 (in terms of both 
% of positive cells and MFI) and levels of degranulation 
in the presence of EA cells that reached those observed 
in the presence of optimal doses of rIL-15. Moreover, 
rIL-27 promoted an upregulation of DNAM-1 expression 
(Figure 4C) that progressively increased by reducing the 
concentration of rIL-15. The ability of rIL-27 to increase 
NK cell degranulation in the presence of suboptimal doses 
of rIL-15 (1 ng/ml) was confirmed using as targets both 
MMECs and MGECs (Figure 5).
rIL-27 up-regulates PD-L2 and HLA class I 
expression in tumor endothelial cells 
We analyzed whether the positive effects of the rIL-
151 ng-rIL-27100 ng combination on NK cell functions could 
be associated with side effects such as the up-regulation 
of ligands capable to inhibit the NK cell-mediated attack. 
The EA cell line was analyzed for the expression of 
the PD-Ls and HLA-II immune-checkpoints molecules, 
Figure 1: Susceptibility of MMECs to NK-mediated killing and activating receptors involved. (A) PBMCs from 3 healthy 
donors were stimulated with rIL-15 (20 ng/ml) and analyzed for their cytolytic activity (51Cr release assay) against MMECs derived from 
4 different patients (MMEC1-4), (E:T ratio 80:1) in the absence (white bars) or in the presence of anti-HLA-I mAbs (gray bars). Mean (3 
healthy donors in duplicate), 95% confidence intervals and significance are indicated. *p < 0.05. (B) IL-15 activated NK cell populations 
were analyzed for their cytolytic activity (51Cr release assay) against MMECs and EA cell line (E:T ratio 20:1) in the absence (white bars) 
or in the presence of mAbs (10 μg/ml) specific for the indicated activating NK receptors used alone or in combination. Mean (3 healthy 
donors in duplicate), 95% confidence intervals and significance are indicated. *p < 0.05.
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as well as of HLA-I. As shown in Figure 6, EA cells 
constitutively expressed PD-L1, PD-L2 and HLA-I. Similar 
to what has been demonstrated in tumor cells [34, 40], 
rIFN-γ up-regulated the PD-Ls and HLA-I expression 
and de novo induced that of HLA-II, whereas rTNFα  was 
effective only in the induction of HLA-I expression.
EA cells were treated with culture supernatants 
derived from NK cells stimulated with the rIL-151 ng-
rIL-27100 ng combination. EA cells did not modify the 
expression of PD-L1 and HLA-II, whereas they showed 
upregulation of PD-L2 and HLA-I (Figure 6) at levels 
comparable to those obtained using rIFN-γ. It is of note 
that a similar effect was obtained using supernatants from 
NK cells stimulated with rIL-27100 ng but not with rIL-151 ng 
(Figure 6). Moreover, negligible amounts of IFN-γ were 
detected in the supernatants of NK cells stimulated with 
rIL-151 ng and rIL-27100 ng, both used alone or in combination 
(Supplementary Table 1). Overall the data suggested that 
the increased expression of PD-L2 and HLA-I in EA 
cells treated with NK supernatants was mainly rIL-27 
dependent and IFN-γ/IL-15 independent. To confirm 
this hypothesis, EA cells were directly stimulated with 
the cytokines either alone or in combination (Figure 7 
and Supplementary Figure  4). rIL-27 alone did not modify 
the expression of PD-L1 and HLA-II, whereas increased 
that of PD-L2 and HLA-I that reached levels comparable 
to those obtained using the rIL-151ng-rIL-27100 ng 
combination. On the contrary, rIL-15 alone had no effect 
even at the highest (20 ng/ml) concentration used. 
 The rIL-27 capability of up-regulating HLA-I and PD-
L2 molecules in tumor endothelium was confirmed using 
three different MMECs that were treated with rIL-27100 ng 
(or IFN-γ, as control) (Figure 8). According to results 
obtained on EA, rIL-27 did not significantly modify the 
PD-L1 expression whereas it up-regulated HLA-I expression 
in all MMECs, although at different extent. Increased 
PD-L2 expression was detected in MMEC7 that derived 
from a patient with MM in progression and unresponsive 
to chemotherapy. In line with results on EA, IFN-γ induced 
PD-L1 and HLA-I expression on MMEC6 and MMEC7. 
Interestingly however, on MMEC8 derived from a 
patient in relapse IFN-γ increased PD-L1 but not HLA-I 
expression.  
DISCUSSION 
Multiple Myeloma remains an incurable disease 
and novel therapeutic strategies did not lead to a survival 
higher than 5 years in the adult [41]. Some benefits have 
been achieved using drugs such as lenalidomide that 
can exert several immunomodulatory effects, including 
the exacerbation of NK cell-mediated cytotoxicity 
against MM [42]. In vitro studies and clinical trials have 
also explored the possible efficacy of novel strategies 
combining standard treatments with emerging therapies 
aimed to interrupt receptors/ligands interactions such 
as PD1/PD-L1 [43] or KIRs/HLA-I [44], which are 
capable of limiting the anti-tumor function of immune 
effectors. NKp46, NKG2D and DNAM-1 activating 
receptors recognize specific ligands on MM cell surface 
and unchain the anti-MM activity of NK cells [45, 46]. 
In particular, as for other malignancies [21, 22], a pivotal 
role in the NK-mediated aggression of MM is played 
by DNAM-1/PVR interactions. These are required for 
optimal anti-MM efficacy of standard therapies based on 
the administration of cyclophosphamide and bortezomib. 
Moreover, it has been shown that different classes 
of therapeutic agents upregulate DNAM-1 as well as 
Table 2: NKG2D and DNAM-1 ligands expression in endothelial cells 
ULBP-1 ULBP-2 ULBP-3 ULBP-4 MICA PVR Nectin-2
MMEC1 (−) 10 11 (−) (−) 186 40
MMEC2 (−) ND ND ND ND 147 43
MMEC3 (−) 7 13 (−) 12 93 44
MMEC4 (−) (−) 10 (−) ND 93 24
MMEC5 (−) (−) (−) (−) (−) 65 23
cr-MMEC (−) (−) (−) (−) (−) 38 36
MGEC1 (−) 12 (−) (−) (−) 57 24
MGEC2 ND (−) 9 ND ND 35 21
MGEC3 (−) 10 10 13 (−) 49 19
MGEC4 (−) (−) (−) 6 (−) 61 40
MGEC5 (−) 6 (−) ND ND 57 13
IDAEC ND (−) (−) ND ND 10 14
EA (−) 12 24 (−) (−) 257 57
Endothelial cells used in this study were analyzed by flow cytometry for the expression of the indicated ligands. Values indicate 
the MFI. Undetectable = (–), ND = not determined. For EA cell line values represent the mean of 10 different experiments.
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NKG2D ligands [47, 48], thus strengthening the concept 
that NK cells might truly represent powerful adjuvant 
arms against MM. 
Our present study suggests that NK cell-based 
immunotherapy might also be effective in MM patients 
because of the capability of NK cells to kill tumor-
associated endothelial cells, which are involved in neo-
angiogenesis and represent a source of soluble factors 
involved in paracrine loops mediating plasma cell 
proliferation and spread [49, 50]. We showed that activated 
NK cells efficiently killed MMECs (and MGECs) thanks 
to the cooperation of multiple triggering receptors. These 
include NKp30 whose known ligand B7-H6, however, 
is virtually absent on tumor endothelium, suggesting the 
possible existence of novel unidentified NKp30 specific 
ligand/s. NKG2D ligands were weakly expressed on 
MMECs surface, whereas all MMECs analyzed expressed 
good levels of both PVR and Nectin-2, ligands of DNAM 
that clearly contributed to killing of MMECs. A striking 
exception was represented by MMEC1 and MMEC2 that 
resulted poorly susceptible to lysis despite the expression 
of high levels of PVR. DNAM-1/PVR interaction is crucial 
for recognition and killing of different tumors [3]. It is 
of note however that its action could be counteracted by 
the engagement of TIGIT [20, 51] an inhibitory receptor 
which recognizes nectin-3 as well as PVR and nectin-2, 
with higher affinity than DNAM-1 [51]. Thus the different 
susceptibility to killing of PVRhigh MMECs might be 
Figure 2: PVR and nectin-2 expression in MMECs and normal endothelial cells. (A) MMECs (black triangles), cr-MMEC, 
MGECs, IDAEC (gray triangles) and EA (white triangles) were analyzed by flow cytometry for the expression of PVR and Nectin-2. Mean 
and 95% confidence intervals are indicated. *p < 0.05, **p < 0.0001, ****p < 0.001, p = ns means not significant. (B) Representative 
cytofluorimetric analysis of PVR, Nectin-2, DNAM-1-Fc and NKp30-Fc staining in MMECs, cr-MMEC, IDAEC and EA. White profiles 
refer to cells incubated with isotype-matched mAbs. Value inside each histogram indicates the Median Fluorescence Intensity (MFI).
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linked to different combinations of PVR-specific paired 
receptors on NK cells [51]. Another possibility is that in 
some patients the function of TIGIT may dominate due to 
the expression of nectin-3 on MMECs. Both hypotheses 
are currently under investigation.
In line with data obtained from the 
immunohistochemical analysis of primary glioblastoma 
specimens [8], PVR showed a high expression in tumor-
associated endothelium from MM BM aspirates. In a 
physiological context, DNAM-1/PVR interactions have 
been shown to promote the transendothelial migration 
process of monocytes [52]. It would be of interest to 
understand whether the high expression of PVR in MMECs 
might improve migration of monocytes, which in the tumor 
microenvironment tend to differentiate into macrophages 
and acquire a M2 tumor-promoting functional polarization 
[53, 54]. Moreover, PVR expression might directly favor 
the function of MMECs thus contributing to the formation 
Figure 3: Comparison between rIL-27 and rIL-15-mediated stimulation of resting NK cells. NK cells purified from 
healthy donors were stimulated with rIL-15 (20 ng/ml) and rIL-27 (100 ng/ml) used alone or in combination. Cells were analyzed for (A) 
cytotoxicity against EA cells (51Cr release assay, E:T ratio 20:1),  (B–G) expression of the indicated surface molecules (flow cytometry). 
Culture supernatants were analyzed for the presence of IFN-γ (ELISA assay) (H). Mean and 95% confidence intervals are indicated. 
*p < 0.05, p = ns means not significant. Data shown are pooled from 6 independent experiments performed using NK cells from 6 unrelated 
healthy donors.
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Figure 4: rIL-27 plus suboptimal doses of rIL-15 induce NK cell activation. NK cells purified from healthy donors were 
stimulated with decreasing concentrations of rIL-15 alone (circle) or in combination with rIL-27 (100 ng/ml) (triangle). Cells were analyzed 
for (A–C) surface phenotype (flow cytometry), (D) release of cytotoxic granules in the presence of EA cells (CD107a assay).  Mean and 
95% confidence intervals are indicated. *p < 0.05, **p < 0.01. p = ns means not significant. Data shown are pooled from 6 independent 
experiments performed using NK cells from 6 unrelated healthy donors.  
Figure 5: NK cell degranulation in the presence of MMECs and MGECs is increased by rIL-27 and suboptimal 
concentrations of rIL-15. NK cell populations derived from 2 healthy donors (black and white circles) were stimulated with suboptimal 
concentrations (1 ng/ml) of rIL-15 alone or in combination with rIL-27 (100 ng/ml). Cells were analyzed for degranulation (CD107a assay) 
in the presence of the indicated MMECs and MGECs.  Controls (CTR) represent NK cell degranulation of NK cells stimulated with rIL-15 
and rIL-27 in the absence of target. Data shown are pooled from 2 independent experiments. Mean are indicated.
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of the complex architecture of tumor vasculature. In this 
context, different studies showed that PVR improve tumor 
cell invasion, being localized at the migrating cellular front 
together with actin and alphav-integrin, known mediators 
of motility and adhesion [55–57]. Thus, it should be 
taken into consideration that therapies upregulating PVR 
expression could on one side potentiate the NK cell-
mediated killing by improving the formation of effective 
immune synapses, on the other they may favor functional 
capabilities of MM and MMECs. 
DNAM-1/PVR interactions also occur during the 
crosstalk between NK cells and Dendritic cells (DC) 
[58, 59] or Macrophages [60, 61]. During their activation 
these antigen presenting cells (APC) release different 
cytokines capable of amplifying NK (and T) cell-mediated 
responses. These include IL-27 that is of interest in tumor 
immunology because it combines immunostimulatory and 
anti-angiogenic properties [30, 31]. We have analyzed the 
effects of IL-27 on NK cell functions, using the cytokine 
alone or in combination with IL-15. IL-15 represents a 
promising immunostimulatory adjuvant for therapies 
[62, 63], and a clinical grade formulation is currently 
available. However, different data suggested that IL-15 is 
also endowed with strong pro-angiogenic effects [64, 65]. 
According to previous data, we showed that optimal 
doses of IL-15 efficiently stimulate NK cells and increase 
their killing of MMECs. Interestingly, a similar cytolytic 
potential was observed in NK cells stimulated with IL-27 
and suboptimal doses of IL-15 (IL-151 ng and IL-27100 ng). 
This effect was paralleled by a trend toward the increased 
expression of DNAM-1, NKp30, NKG2D and NKp46 
activating receptors. In this context, and according with 
previous published data [66], the upregulation of NKp46 
in NK cells was mainly IL-27-dependent. 
In some instances, IL-27 did not ameliorate the 
effect of optimal doses of IL-15. For example, a significant 
increase of DNAM-1 expression could be appreciated only 
when IL-27 was used in combination with suboptimal 
doses of IL-15 (see Figures  3 and 4). This observation 
could be partially due to the fact that, in NK cells, IL-15- 
and IL-27-mediated signals share some transducing 
molecules such as JAK1 and STAT5 [67, 68]. Moreover, 
IL-15 might play a role in regulating IL-27R expression 
and/or function (under investigation).
NK cells stimulated with IL-27 and suboptimal 
doses of IL-15, release negligible amounts of IFN-γ, 
which is considered the best inducer of HLA-I molecules 
as well as of the PD-Ls immune-checkpoints ligands [34]. 
Figure 6: Constitutive or inducible expression of PD-Ls, HLA-II and HLA-I in EA cell line. The EA cell line untreated 
(CTR), treated with IFN-γ, TNF-α or culture supernatants from NK cells unstimulated (none) or stimulated with the indicated cytokines, 
was analyzed by flow cytometry for the expression of PD-Ls, HLA-II and HLA-I. Panel A and B show two independent experiments 
performed using NK cells purified from two unrelated healthy donors. White profiles refer to cells incubated with isotype-matched mAbs. 
Values inside each histogram indicate the MFI.
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In EA and MMECs, IL-27 (either alone or in combination 
with IL-151ng) did not upregulate the expression of PD-L1 
or induce that of HLA-II. On the other hand, it upregulated 
the expression of HLA-I, as previously demonstrated in 
normal endothelium (HUVEC cells) [69]. Moreover our 
study highlighted a peculiar function of this cytokine, i.e. 
the capability of upregulating the expression of PD-L2 on 
tumor endothelium. It is of note that previous published 
data suggest that IL-27 function might vary depending 
on target cell type and cytokine milieu. Indeed, IL-27 has 
been shown to drive upregulation of HLA-I also in chronic 
eczema keratinocytes that produced IL-27, but it promoted 
PD-L1 expression in different cell types including CD4+ 
and CD8+ T cells, monocytes, DC and tumor cells [29, 30, 
70]. Thus, similar to IFN-γ (and TNF-α), IL-27 might exert 
possible side effects modulating the expression in MMECs 
of HLA-I, which downregulates the NK cell function, 
and PD-L2 that controls the duration and amplitude of 
both CD8+ T and NK cell functions. In this context, it 
has been shown that in MM patients more than 50% of 
peripheral blood NK cells express PD-1 [43], the PD-Ls 
receptor, although at levels lower than PD1+ NK cells 
detected in normal individuals or in different pathological 
conditions [72]. Thus, standard or emerging therapeutic 
approaches should not disregard the possible induction 
of a cytokine storm that might shape immune responses 
against tumor cells and/or tumor-associated endothelium. 
As for IFN-γ [71] the IL-27 capability of upregulating 
immune checkpoint ligands on tumor endothelium, may 
greatly vary among patients. Notably, during anti-tumor 
immune responses IL-27 may act earlier than IFN-γ, being 




Bone marrow (BM) aspirates were obtained from 
nine MM patients fulfilling the International Myeloma 
Working Group diagnostic criteria for multiple myeloma 
(MM). MM patients, enrolled at diagnosis (MM1-6, 
MM9), in progression because unresponsive to therapy 
(MM7), in relapse (MM8), were characterized by active, 
symptomatic disease (D&S stage II-III). Additional BM 
aspirates were obtained from a MM patient in complete/
objective remission (cr-MM), seven patients with 
monoclonal gammopathy of undetermined significance 
(MGUS), and a patient with anemia due to iron deficiency 
(IDA). Approval from the Ethics Board was obtained 
(N°4220/2013), and patients were asked to provide 
their written informed consent in accordance with the 
Declaration of Helsinki. 
Cells used in the study
Primary endothelial cells (ECs) were obtained 
from BM of patients as described [37]. Briefly, ECs 
were purified from BM-derived mononuclear cells by 
immunoselection, using magnetic microbeads (Dynal, 
Oslo, Norway) coated with Ulex europaeus agglutinin-1 
lectin (UEA-1, Sigma Chemical), whose receptor is 
selectively and highly expressed by endothelial cells. 
ECs bound to microbeads were cultured in complete 
DMEM medium supplemented with 20% of heat-
inactivated fetal bovine serum (FBS) to allow cells to 
adhere, spread and grow. Endothelial cells were growth 
Figure 7: rIL-27 upregulates PD-L2 and HLA-I in EA cell line. The EA cell line untreated (white bar) or treated with rIL-15 
and rIL-27 alone or in combination (gray bars) was analyzed by flow cytometry for the expression of PD-Ls, HLA-II and HLA-I. MFI fold 
increase is shown. Mean and 95% confidence intervals are indicated. *p < 0.05. Data shown are pooled from 4 independent experiments.
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for at least one passage and their purity was confirmed 
by flow cytometry (FACScalibur, Becton Dickinson and 
Co, Mountain View, CA) analyzing the presence of the 
ECs markers factor VIII–related antigen (anti-human 
Von Willebrand factor mAb, Beckman Coulter, Marseille, 
France) and CD105 (anti-human CD105 mAb, Beckman 
Coulter), and the absence of CD14 (anti-human CD14 
mAb, Becton Dickinson) and CD38 (anti-human CD38 
mAb, Becton Dickinson) molecules. ECs viability was 
assessed by trypan blue exclusion staining (> 97% viable 
cells). The human endothelial (EA.hy926, henceforth 
named EA) and erythroleukemia (K562) cell lines were 
purchased from American Type Culture Collection (ATCC).
After approval by the Ethics Board (N°39/2012) and 
informed consent, buffy coats were obtained from healthy 
volunteer blood donors admitted at the transfusion center of 
IRCCS AOU San Martino-IST (Genova, Italy). Peripheral 
blood mononuclear cells (PBMC) were isolated on Ficoll-
Hypaque gradients and frozen at –80°C. Upon arrival of 
MMECs in the laboratory by express courier, PBMC were 
thawed and either stimulated with cytokines or used to 
purify NK cells (Human NK Cell Isolation kit, Miltenyi 
Biotec, GmbH, Bergisch Gladbach, Germany) as previously 
described [53]. The degree of purity of the isolated NK cells 
(CD3-, CD56+, NKp46+) was superior to 98%.
Monoclonal antibodies and cytokines
The following mAbs were produced in our laboratory: 
A6136 (IgM) and 6A4 (IgG1) (anti-HLA class I-A, -B, -C 
and HLA-E), FST24 (IgG2b, anti-HLA-II), A6/220 (IgM, 
anti-CD56), BAB281 (IgG1) and KL247 (IgM) (anti-
NKp46), AZ20 (IgG1) and F252 (IgM) (anti-NKp30), 
BAT221 (IgG1, anti-NKG2D), KRA236 (IgG1) and F5 
(IgM) (anti-DNAM-1), BAM195 (IgG1, anti-MICA), 
M5A10 (IgG1, anti-PVR), U191 (IgM, anti-Nectin-2), 
c227 (IgG1, anti-CD69). MAB1380 (IgG2a, anti-ULBP1), 
MAB163903 (IgG2A, anti-ULBP2), MAB1517 (IgG2A, 
Figure 8: Effect of rIL-27 on PD-Ls and HLA-I expression in MMECs. Three MMECs either untreated (open triangle) or 
treated for 5 days with IFN-γ  (black triangle) or IL-27 (open circle) were analyzed by flow cytometry for the expression of PD-Ls and 
HLA-I. Percentage of positive cells or MFI is indicated. 
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anti-ULBP3) and M475 (IgG2B, anti-ULBP4) mAbs were 
purchased from R&D System Inc., (Minneapolis, MN, 
USA); anti-CD107a-PE and anti-CD56-PC5 mAbs were 
purchased from Becton Dickinson. Anti-PD-L1.3.1 (IgG1, 
anti-PD-L1) and anti-PD-L2 (IgG1, anti-PD-L2) were 
generated in D. Olive’s lab. 
Human recombinant cytokines were purchased 
from PeproTech (rIL-15, rIFN-γ  and rTNFα) MBL 
International (rIL-18) and R&D Systems (rIL-27). 
Flow cytometry, cytolytic and ELISA assays 
For one-color immunofluorescence and 
cytofluorimetric analysis (FACSCalibur Becton Dickinson) 
cells were stained with the appropriate mAbs or isotype 
matched controls followed by PE-isotype-specific goat anti-
mouse second reagent (Southern Biotechnology Associated, 
Birmingham, AL). On every experimental session, the 
flow cytometer performances were monitored and the 
reproducibility of the fluorescence intensity was aligned by 
calibrated microsphere (Becton Dickinson). ECs were gated 
on the basis of physical parameters (SSC = Side Scatter; 
FSC = Forward scatter) to detect viable cells. To verify the 
appropriateness of the gating strategy cells were stained (10 
minutes at the room temperature) with Annexin V and To-
Pro-3 Iodide (Life Technologies, CA, USA).
Purified NK cells were cultured for 2 days in the 
presence of recombinant cytokines to obtain polyclonal 
activated NK cell populations, which were analyzed for 
their cytolytic activity against target cells using a 4 h 51Cr-
release assay [21]. For CD107a (LAMP-1) degranulation 
assay NK cells were incubated for three hours with target 
cells in the presence of a PE-conjugated anti-human 
CD107a (IgG1; BD Biosciences).
The IFN-γ enzyme-linked immunosorbent 
human assay (ELISA) was performed according to the 
manufacturer’s instruction (Life Technologies). 
Cell transfectants and chimeric receptors 
The BW5147/B7-H6+ stable cell transfectant 
was prepared by retrovirus gene transfer using a B7-H6 
ORF cDNA obtained by RT-PCR from the MM6 human 
myelomonocytic cell line and subcloned in pMXs-IG 
(IRES-GFP) retrovirus vector (kindly provided by Dr. 
Kitamura, Tokyo, Japan). The empty vector pMXs-IG 
was used to generate the negative control (mock cell 
transfectant). DNAM1-Fc and  NKp30-Fc were obtained 
in our lab fusing the extracellular region of the receptor 
with a mutated human IgG1 Fc portion that lack the ability 
to bind FcRs [52, 73].
Real-time PCR
Total RNA was extracted from K562 and EA cell 
lines and from immature dendritic cells (iDC) using 
RNAeasy Mini Kit (Qiagen, Hilden, Germany) according 
to manufacturer’s instructions. Starting from 1 μg RNA, 
oligodT-primed cDNA was prepared using Transcriptor 
First Strand Synthesis Kit (Roche diagnostic, Mannheim, 
Germany). The expression of B7-H6 and HPRT1 
(hypoxanthine phosphoribosyltransferase 1) transcripts 
was assessed by real-time PCR with the Taqman Gene 
expression assays (Hs02340611_m1 and Hs99999909_
m1, respectively) and Express qPCR SuperMix (Thermo 
Fisher Scientific, Waltham, MA, USA). Samples were 
run on a ViiA 7 Real-Time PCR System (Thermo Fisher 
Scientific). Each reaction was performed in triplicate 
and each sample was analysed in three independent 
experiments. Relative expression of B7-H6 transcript 
was determined in each sample by normalization with 
respect to the HPRT1 gene, according to the standard 
∆CT method.
Statistical analysis
Statistical analysis with level of significance (p) and 
graphic representation were performed using Wilcoxon-
Mann-Whiteny p-value test (non-parametric significance 
test) and GraphPad Prism 6 (GraphPad Software La 
Jolla, CA). 
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